Futibatinib (Lytgobi) for cholangiocarcinoma

Abstract

STRUCTURE: Futibatinib (brand name LytgobiTM) is a small molecule kinase inhibitor with the molecular formula C22H22N6O3 and a molecular mass of 418.45 g/mole. The drug is a pyrazolo[3,4-d]pyrimidine derivative with an attached α,β-unsaturated amide warhead, also called a Michael acceptor, that forms a covalent bond with a cysteine residue in the fibroblast growth factor receptor (FGFR) protein-tyrosine kinase glycine-rich loop.